Evaluation of patients diagnosed with intermediate - high risk pulmonary thromboembolism

Abstract

Aims: In this study we aimed to share our treatment approach in patients with intermediate -high risk pulmonary embolism (PE). Methods: This is a single center retrospective observational study. Patients diagnosed with PE at Akdeniz University Hospital between January 1, 2015, and January 1, 2021, were retrospectively analyzed. Patients whose diagnosis of PE was confirmed by computed tomography angiography (CTA) or perfusion/ventilation scintigraphy were considered to have PE. Patients with intermediate-high risk were included in the study. Patients with a diagnosis of low-risk, low-intermediate risk, high-risk PE, patients younger than 18 years of age, and pregnant were excluded from the study. Results: A total of 150 patients, 64 (42.7%) male and 86 (57.3%) female, with a mean age of 62.2±16.2 years, who met the criteria of these patients were included. 22.7% (34) of the patients received thrombolytic therapy. While 67.7% (23) of the patients who received thrombolytic therapy received half-dose (50mg rt-PA) thrombolytic therapy, 32.3% (11) received full-dose (100mg rt-PA) thrombolytic therapy. Major hemorrhage (3 intracranial hemorrhages, 1 femoral hemorrhage) was detected in 11.7% (4) of the patients who received thrombolytic therapy. Conclusion: In conclusion, no significant effect of thrombolytic therapy or full or half dose on mortality and long-term TTE findings was found in the intermediate -high risk group.